- Home
- CTOS vs DVAX Comparison
CTOS vs DVAX Comparison
Compare CTOS & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOS
- DVAX
- Stock Information
- Founded
- CTOS 1988
- DVAX 1996
- Country
- CTOS United States
- DVAX United States
- Employees
- CTOS N/A
- DVAX N/A
- Industry
- CTOS Diversified Commercial Services
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- CTOS Consumer Discretionary
- DVAX Health Care
- Exchange
- CTOS Nasdaq
- DVAX Nasdaq
- Market Cap
- CTOS 1.4B
- DVAX 1.2B
- IPO Year
- CTOS N/A
- DVAX 2004
- Fundamental
- Price
- CTOS $6.44
- DVAX $10.15
- Analyst Decision
- CTOS Buy
- DVAX Buy
- Analyst Count
- CTOS 3
- DVAX 4
- Target Price
- CTOS $7.33
- DVAX $26.50
- AVG Volume (30 Days)
- CTOS 768.1K
- DVAX 1.3M
- Earning Date
- CTOS 10-27-2025
- DVAX 11-06-2025
- Dividend Yield
- CTOS N/A
- DVAX N/A
- EPS Growth
- CTOS N/A
- DVAX N/A
- EPS
- CTOS N/A
- DVAX N/A
- Revenue
- CTOS $1,901,675,000.00
- DVAX $316,268,000.00
- Revenue This Year
- CTOS $13.58
- DVAX $23.23
- Revenue Next Year
- CTOS $5.18
- DVAX $16.57
- P/E Ratio
- CTOS N/A
- DVAX N/A
- Revenue Growth
- CTOS 6.21
- DVAX 26.66
- 52 Week Low
- CTOS $3.17
- DVAX $9.20
- 52 Week High
- CTOS $6.73
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- CTOS 54.04
- DVAX 53.08
- Support Level
- CTOS $6.31
- DVAX $9.71
- Resistance Level
- CTOS $6.63
- DVAX $10.12
- Average True Range (ATR)
- CTOS 0.25
- DVAX 0.23
- MACD
- CTOS -0.00
- DVAX 0.03
- Stochastic Oscillator
- CTOS 53.60
- DVAX 67.69
About CTOS Custom Truck One Source Inc.
Custom Truck One Source Inc is a one-stop-shop provider of specialty equipment in the electric utility transmission and distribution, forestry, telecom, waste management, rail, and infrastructure end-markets in North America. The company's segment includes Equipment Rental Solutions (ERS), Truck and Equipment Sales (TES), and Aftermarket Parts and Services (APS). It generates maximum revenue from the TES segment. Geographically, it derives a majority revenue from the United States.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.